Detailed Programme

09:30 – 10:00 | Registration of participants

2019 in pharmaceutical industry – new challenges, opportunities  and risks


Irena Rej

Prezes Izby Gospodarczej “FARMACJA POLSKA”
10:30 – 11:10 | Most important recent changes in control concerning pharmaceutical industry
  • State drug policy,
  • Pharmaceutical law amendments – What’s behind us? What’s coming? Will  Minister of Justice manage toclose down  the reversed chain

Juliusz Krzyżanowski

Senior Associate, Baker & McKenzie Krzyzowski i Wspolnicy sp.k.

Paweł Hincz

Partner, Head of Life Sciences, Baker & McKenzie Krzyzowski i Wspolnicy sp.k.
11:10 – 11:45 | What’s new in treatment access issue?
  • Refund updates
  • Patients’ rights news

Natalia Łojko

Senior Associate, Radca prawny, KRK Kieszkowska Rutkowska Kolasiński
11:45 – 12:20 | Key problems for wholesaler’s and drugs distribiutors market
  • How the legal dispute about interpretation of provisions on 1% of drug stores in voivodeship has ended?
  •  Contractor supply models and inspections of    pharmaceutical wholesalers?

Magdalena Bąkowska

Senior associate, Adwokat, KRK Kieszkowska Rutkowska Kolasiński
12:20 – 12:30 | Coffee break
12:30 – 12:50 | Recent trends in advertisement of drugs and other health products
  • Authority actions and planned legislation amendments in terms of advertisement
  • Rx and OTC products web advertisement
  • Recent case-law of drug advertisement and other health products

dr Andrzej Balicki

Partner, DLA Piper Wiater Sp. k.


12:50 – 13:25 | Changes within umbrella branding
  • New UPRL Chairman guidelines in terms of umbrella brands
  • Umbrella branding – drugs, medical devices, supplements, cosmetics
  • Introducing and advertising different categories of products under the same umbrella brand

dr Daria Wierzbińska

Radca Prawny, KRK Kieszkowska Rutkowska Kolasiński
15:05 – 15:40 | New challenges in terms of compliance: draft act on collective entity responsiblity
  • Previous provisions, partnership responsibility on UOPZ vs regulations under other jurisdictions
  • Range of designed regulations
  • Implications for Business and required changes within internal SOPs

Marcin Tomasik

Partner, Kancelaria Tomasik Jaworski Sp.p.ka
14:00 – 14:30 | Coffee break
14:30 – 15:05 | Tax ernvironment changes crucial for pharmaceutical industry
  • Fiscal enforced interpretation changes in terms of marketing actions
  • Practical view of split payment
  • Essential tax change projects in the industry

Szymon Bernat

Tax Manager w zespole Life Sciences w KPMG w Polsce
13:25 – 14:00 | Advertising for medical experts – recent trends
  • Recent GIF case laws in reference to drug advertisement
  • Industry codes in relation of company – HCP / HCO
  • Basic tools providing compliance with the law

Bartłomiej Sasin

Associate w Kancelarii Tomasik Jaworski sp. p.
15:40 – 16:15 | Planned changes within clinical studies research – changes in pharmaceutical law
  • Range of planned changes
  • Impact of changes on the conducted research works
  • When will the changes be implemented?

Noemi Chudzik

LL.M., Radca Prawny, Partner, Kancelaria Chudzik i Wspólnicy Radcowie Prawni
16:15 | End of conference